SOPs for Expedited Adverse Event Handling in Clinical Trials

Published on 23/12/2025

Designing SOPs for Expedited Adverse Event Handling in Clinical Trials

Table of Contents

Why SOPs Are Critical for Expedited AE Handling

Standard Operating Procedures (SOPs) form the backbone of pharmacovigilance systems in clinical research. Regulators including the FDA, EMA, MHRA, and CDSCO expect sponsors and CROs to maintain written SOPs that define workflows for adverse event (AE) and serious adverse event (SAE) reporting. When it comes to expedited reporting timelines (7 days, 15 days, and 24-hour notification windows), SOPs ensure compliance, consistency, and inspection readiness.

Without SOPs, teams risk inconsistent classification of SAEs and SUSARs, missed deadlines, and inspection findings that may jeopardize trial approval. Well-drafted SOPs define who does what, when, and how, leaving no ambiguity in handling expedited reports. For global trials, SOPs also harmonize requirements across jurisdictions, ensuring investigators and sponsors align with regulatory timelines.

Moreover, SOPs protect sponsors legally by demonstrating due diligence. In regulatory inspections, auditors often ask to review expedited reporting SOPs and verify that they have been implemented, trained, and followed.

Core Elements of an Expedited AE Handling SOP

To be effective, SOPs for expedited AE handling must address the following components:

Scope and applicability: Define which studies, sites, and personnel

are covered.

Definitions: Clearly define AE, SAE, SUSAR, expectedness, seriousness, and causality terms.

Responsibilities: Assign duties to investigators, sponsors, CROs, and safety departments.

Timelines: Include global rules (24-hour investigator notification, 7/15-day SUSAR reports).

Workflows: Step-by-step processes for intake, assessment, reporting, and follow-up.

Documentation: Templates for SAE forms, narratives, and regulatory submissions.

Training: Define how staff are trained on expedited AE handling.

Quality control: Monitoring, reconciliation, and audits to ensure SOP adherence.

For instance, an SOP should state: “Investigators must notify the sponsor of all SAEs within 24 hours of awareness. Sponsors must assess causality and expectedness within 48 hours and submit expedited reports to regulatory agencies within required timelines.”

Sample Workflow for SAE/SUSAR Reporting

The following workflow illustrates a standard expedited SAE handling process:

Investigator: Detects SAE → reports to sponsor within 24 hours.
Sponsor Safety Team: Confirms seriousness, causality, and expectedness within 48 hours.
Regulatory Submission: Fatal/life-threatening SUSAR → 7-day report; all other SUSARs → 15-day report.
Follow-up: Submit additional information (labs, autopsy, imaging) as soon as available.
Reconciliation: Align CRFs, safety database, and TMF monthly.

This workflow, embedded in SOPs, ensures that reporting clocks are met consistently and that documentation is audit-ready.

Case Example: Implementing an Expedited AE SOP in Oncology

Scenario: In a Phase II immunotherapy trial, a patient develops autoimmune hepatitis requiring hospitalization. The event is serious, related, and unexpected → SUSAR.

Investigator Action: SAE reported to sponsor within 24 hours via SAE form.
Sponsor Review: PV physician confirms causality and expectedness within 48 hours.
Regulatory Submission: SUSAR submitted to FDA, EMA, MHRA, and CDSCO within 7 days.
Follow-up: Lab reports, biopsy results submitted in 8 additional days.
SOP Check: Internal audit verifies compliance with timelines.

This case illustrates how SOP-driven workflows prevent delays, ensure consistency, and withstand inspection scrutiny.

Inspection Readiness: What Auditors Expect

During inspections, regulators review expedited AE SOPs for the following:

Clear alignment with GCP and ICH E2A/E2D guidelines.
Evidence of training logs for investigators and staff.
Proof of adherence to 24-hour, 7-day, and 15-day reporting rules.
Consistency between SOPs, CRFs, narratives, and safety databases.
Evidence of reconciliation and periodic review.

Common inspection findings include SOPs that are too generic, lack of clarity on responsibilities, or evidence that staff were unaware of expedited reporting timelines. Therefore, SOPs must be both written and operationalized.

Best Practices for SOP Development

To build robust SOPs for expedited AE handling, sponsors and CROs should:

Engage cross-functional teams (clinical operations, PV, QA, regulatory) in SOP drafting.
Incorporate country-specific timelines (e.g., CDSCO’s 24-hour + 10-day causality rule).
Use decision trees and flowcharts to simplify classification steps.
Include templates for SAE forms, narratives, and expedited submission logs.
Schedule periodic SOP reviews to align with updated FDA, EMA, or ICH guidelines.

Public resources such as the WHO International Clinical Trials Registry provide valuable examples of safety reporting obligations that can guide SOP updates.

Key Takeaways

SOPs for expedited AE handling are essential for regulatory compliance and patient safety. Clinical teams should:

Define clear workflows and responsibilities in SOPs.
Embed regulatory timelines (24 hours, 7 days, 15 days) in procedures.
Train staff and monitor compliance continuously.
Reconcile safety data across EDC, PV, and TMF systems regularly.
Audit SOPs periodically to ensure alignment with evolving global rules.

By implementing well-drafted and operational SOPs, sponsors and CROs ensure consistent expedited reporting, inspection readiness, and protection of trial participants worldwide.